mapracorat (BOL-303242-X) / Bayer - LARVOL DELTA

Biased regulation of glucocorticoid receptors signaling. (PubMed, Biomed Pharmacother) - "Based on the bias regulation of GR, selective GR agonists and modulators (SEGRAMs) were developed to bias therapeutic outcomes toward expected outcomes (e.g., anti-inflammation and immunoregulation) by influencing GR-mediated gene expression. This paper provides a review of the bias regulation and mechanism of GR and the research progress of drugs."

Journal • Review • Immune Modulation • Inflammation

Identification of the selective glucocorticoid receptor agonist Mapracorat as potential new drug for chronic wound therapy (ESDR 2022) - "Mapracorat showed good or excellent activity with almost 50% of exudates. To select the patients best suited for therapy with this compound, theranostic pretesting is recommended."

IL1B

Dimerization of glucocorticoid receptors and its role in inflammation and immune responses. (PubMed, Pharmacol Res) - "Furthermore, some studies have shown that some selective glucocorticoid receptor agonists and modulators (SEGRAMs) have good separation characteristics (i.e., preferentially mediate the transrepression of proinflammatory genes or preferentially activate anti-inflammatory target genes). This article reviewed the formation of GR dimers, the role of GR dimers in the inflammation and immune responses, and the progress of SEGRAMs to provide novel ideas for further understanding the anti-inflammatory mechanism of GR and the development of SEGRAMs."

Journal • Review • Allergic Rhinitis • Asthma • Immunology • Inflammation • Inflammatory Arthritis • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology

Efficacy and safety of different concentrations of mapracorat ointment over 4 weeks in atopic dermatitis (AD) (clinicaltrials.gov) - P2, N=197; Active, not recruiting -> Completed

Trial completion • Eczema • Immunology